Interview with Gun-Britt Fransson, new Chairman of the Board in Follicum

Report this content

What is your background and what have you done before joining Follicum?
I have a biomedical education with a PhD in Nutrition and have as long as I can remember been convinced that new research can make the world a better place. 

This has been reflected in my over 30-year career in research-leading positions in pharmaceuticals, food and biotechnology. I have held various research-leading positions in KabiPharmacia, within Procordia and Orkla Foods, as well as in Probi AB, a research-based biotechnology company where I acted as Vice President R&D until March this year, and also, for a year, acted as CEO. Another research-based company where I worked as the CEO for 6 years was Alligator Bioscience AB, active in early drug development just like Follicum. In addition to my operational work, I have for the past 25 + years acted as board member and chairman of the board in both small and larger companies, foundations and universities. Examples include Bioinvent, Teknikbrostiftelsen i Lund and Malmö University.

Why did you join Follicum as a Board Member?
I see Follicum as an exciting small company with a big potential. The company has already created interesting and promising data in the areas where it is active, starting within hair growth, and continuing within diabetes. There is a thorough plan laid out for the coming work and a number of opportunities can be seen for the future. The company has furthermore succeeded in attracting highly skilled employees with a great commitment, which I believe is crucial to a company at this stage of development. The very close relationship with university researchers also ensures an influx of new knowledge and allows the company to stay small, limiting the cost structure, something that is a significant advantage in the phase where Follicum is today. To summarize, I see an exciting company with a high possibility to succeed with its plans.

What expertise will you bring to the Follicum Board?
I believe that my experience in strategic management and leadership of research-intense companies will be of value for Follicum. I also believe that the combination of scientific understanding and the ability to translate, communicate and commercialize science that I have acquired during my career, is of high importance to a research-based company in the phase where Follicum is at today. My long experience of board assignments, of strategic planning, organization and motivation of employees should also be of benefit for the activities in the board as well as to the business itself. In addition, I have, during the years built an extensive network of professionals in various research areas and industries, that can be of use when helping to guide Follicum into the future.

For further information, please contact:
Jan Alenfall – CEO, Follicum AB

Telephone: +46 (0)46 - 19 21 97

About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. 


Documents & Links